Combined administration of a mutant TGF-β1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance

Journal of Immunology

Volumn 185, Issue 8, 2010, Pages 4750-4759

  Zhang, Wensheng ^a   Zhang, Dong ^a   Shen, Miaoda ^a   Liu, Yun ^a   Tian, Yan ^a   Thomson, Angus W ^b   Lee, W P Andrew ^a   Zheng, Xin Xiao ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; FC RECEPTOR; HYBRID PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; MUTANT PROTEIN; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH17 CELL; ALLOTRANSPLANTATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL SEPARATION; CYTOLOGY; FLOW CYTOMETRY; GENE TARGETING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MUTATION; PANCREAS ISLET TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION TOLERANCE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL SEPARATION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCK-IN TECHNIQUES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; INTERLEUKIN-6; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; MUTATION; RECOMBINANT FUSION PROTEINS; SIROLIMUS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 78049512513     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000769     Document Type: Article

References (51)

1. Qin, S., S. P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, and H. Waldmann. 1993. "Infectious" transplantation tolerance. Science 259:974-977.
2. Sánchez-Fueyo, A., M. Weber, C. Domenig, T. B. Strom, and X. X. Zheng. 2002. Tracking the immunoregulatory mechanisms active during allograft tolerance. J. Immunol. 168:2274-2281.
3. Zheng, X. X., A. Sanchez-Fueyo, C. Domenig, and T. B. Strom. 2003. The balance of deletion and regulation in allograft tolerance. Immunol. Rev. 196:75-84.
4. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061.
5. Adeegbe, D., A. L. Bayer, R. B. Levy, and T. R. Malek. 2006. Cutting edge: allogeneic CD4+CD25+Foxp3+ T regulatory cells suppress autoimmunity while establishing transplantation tolerance. J. Immunol. 176:7149-7153.
6. Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl. 2003. Conversion of peripheral CD4+CD25-naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198:1875-1886.
7. Li, M. O., Y. Y. Wan, and R. A. Flavell. 2007. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1-and Th17-cell differentiation. Immunity 26:579-591.
8. Blobe, G. C., W. P. Schiemann, and H. F. Lodish. 2000. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342:1350-1358.
9. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179-189.
10. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238.
11. Thomson, A. W., H. R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9:324-337.
12. Coenen, J. J., H. J. Koenen, E. van Rijssen, L. B. Hilbrands, and I. Joosten. 2006. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 107:1018-1023.
13. Battaglia, M., A. Stabilini, B. Migliavacca, J. Horejs-Hoeck, T. Kaupper, and M. G. Roncarolo. 2006. Rapamycin promotes expansion of functional CD4+ CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177:8338-8347.
14. Strauss, L., T. L. Whiteside, A. Knights, C. Bergmann, A. Knuth, and A. Zippelius. 2007. Selective survival of naturally occurring human CD4+CD25+ Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 178:320-329.
15. Wang, T., B. Y. Li, P. D. Danielson, P. C. Shah, S. Rockwell, R. J. Lechleider, J. Martin, T. Manganaro, and P. K. Donahoe. 1996. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 86:435-444.
16. Dodge, I. L., G. Demirci, T. B. Strom, and X. C. Li. 2000. Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation 70:1104-1106.
17. Lawrence, D. A., R. Pircher, C. Krycève-Martinerie, and P. Jullien. 1984. Normal embryo fibroblasts release transforming growth factors in a latent form. J. Cell. Physiol. 121:184-188.
18. Annes, J. P., J. S. Munger, and D. B. Rifkin. 2003. Making sense of latent TGFbeta activation. J. Cell Sci. 116:217-224.
19. Gentry, L. E., N. R. Webb, G. J. Lim, A. M. Brunner, J. E. Ranchalis, D. R. Twardzik, M. N. Lioubin, H. Marquardt, and A. F. Purchio. 1987. Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol. Cell. Biol. 7:3418-3427.
20. Assoian, R. K., A. Komoriya, C. A. Meyers, D. M. Miller, and M. B. Sporn. 1983. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem. 258:7155-7160.
21. Coffey, R. J., Jr., L. J. Kost, R. M. Lyons, H. L. Moses, and N. F. LaRusso. 1987. Hepatic processing of transforming growth factor beta in the rat. Uptake, metabolism, and biliary excretion. J. Clin. Invest. 80:750-757.
22. Wakefield, L. M., T. S. Winokur, R. S. Hollands, K. Christopherson, A. D. Levinson, and M. B. Sporn. 1990. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J. Clin. Invest. 86:1976-1984.
23. Brunner, A. M., H. Marquardt, A. R. Malacko, M. N. Lioubin, and A. F. Purchio. 1989. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J. Biol. Chem. 264:13660-13664.
24. Gentry, L. E., M. N. Lioubin, A. F. Purchio, and H. Marquardt. 1988. Molecular events in the processing of recombinant type 1 pre-pro-transforming growth factor beta to the mature polypeptide. Mol. Cell. Biol. 8:4162-4168.
25. Zheng, X. X., A. W. Steele, P. W. Nickerson, W. Steurer, J. Steiger, and T. B. Strom. 1995. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J. Immunol. 154:5590-5600.
26. Zheng, X. X., M. H. Sayegh, X. G. Zheng, Y. Li, P. S. Linsley, R. Peach, F. Borriello, T. B. Strom, A. H. Sharpe, and L. A. Turka. 1997. The role of donor and recipient B7-1 (CD80) in allograft rejection. J. Immunol. 159:1169-1173.
27. Gao, W., Y. Lu, B. El Essawy, M. Oukka, V. K. Kuchroo, and T. B. Strom. 2007. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am. J. Transplant. 7:1722-1732.
28. Border, W. A., and N. A. Noble. 1994. Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331:1286-1292.
29. Roberts, I. S., C. Burrows, J. H. Shanks, M. Venning, and L. J. McWilliam. 1997. Interstitial myofibroblasts: predictors of progression in membranous nephropathy. J. Clin. Pathol. 50:123-127.
30. Gauldie, J., P. J. Sime, Z. Xing, B. Marr, and G. M. Tremblay. 1999. Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Curr. Top. Pathol. 93:35-45.
31. Boros, P., and J. S. Bromberg. 2009. Human FOXP3+ regulatory T cells in transplantation. Am. J. Transplant. 9:1719-1724.
32. Wood, K. J., and S. Sakaguchi. 2003. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3:199-210.
33. Schmierer, B., and C. S. Hill. 2007. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 8:970-982.
34. Brüggemann, M., G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann, and M. S. Neuberger. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166:1351-1361.
35. Isaacs, J. D., M. R. Clark, J. Greenwood, and H. Waldmann. 1992. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J. Immunol. 148:3062-3071.
36. Greenwood, J., M. Clark, and H. Waldmann. 1993. Structural motifs involved in human IgG antibody effector functions. Eur. J. Immunol. 23:1098-1104.
37. Reddy, M. P., C. A. Kinney, M. A. Chaikin, A. Payne, J. Fishman-Lobell, P. Tsui, P. R. Dal Monte, M. L. Doyle, M. R. Brigham-Burke, D. Anderson, et al. 2000. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 164:1925-1933.
38. Ahuja, S. S., F. Paliogianni, H. Yamada, J. E. Balow, and D. T. Boumpas. 1993. Effect of transforming growth factor-beta on early and late activation events in human T cells. J. Immunol. 150:3109-3118.
39. Nikolaeva, N., F. J. Bemelman, S. L. Yong, R. A. van Lier, and I. J. ten Berge. 2006. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 81:445-454.
40. Huynh, M. L., V. A. Fadok, and P. M. Henson. 2002. Phosphatidylserinedependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 109:41-50.
41. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6:1219-1227.
42. Verhasselt, V., C. Buelens, F. Willems, D. De Groote, N. Haeffner-Cavaillon, and M. Goldman. 1997. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J. Immunol. 158:2919-2925.
43. Yang, X. O., A. D. Panopoulos, R. Nurieva, S. H. Chang, D. Wang, S. S. Watowich, and C. Dong. 2007. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282:9358-9363.
44. Kahan, B. D., S. Gibbons, N. Tejpal, S. M. Stepkowski, and T. C. Chou. 1991. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 51:232-239.
45. Raimondi, G., T. L. Sumpter, B. M. Matta, M. Pillai, N. Corbitt, Y. Vodovotz, Z. Wang, and A. W. Thomson. 2010. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J. Immunol. 184:624-636.
46. Daley, S. R., J. Ma, E. Adams, S. P. Cobbold, and H. Waldmann. 2007. A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts. J. Immunol. 179:3648-3654.
47. Andersson, J., D. Q. Tran, M. Pesu, T. S. Davidson, H. Ramsey, J. J. O'Shea, and E. M. Shevach. 2008. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J. Exp. Med. 205:1975-1981.
48. Zhu, J., J. Wu, E. Frizell, S. L. Liu, R. Bashey, R. Rubin, P. Norton, and M. A. Zern. 1999. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an invivo model of liver fibrosis. Gastroenterology 117:1198-1204.
49. Neef, M., M. Ledermann, H. Saegesser, V. Schneider, and J. Reichen. 2006. Lowdose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J. Hepatol. 45:786-796.
50. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133:775-787.
51. Mitchell, P., B. Afzali, G. Lombardi, and R. I. Lechler. 2009. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr. Opin. Organ Transplant. 14:326-331.